Revenue segments as reported by the company.

Product revenues, net

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development expenses

Acquired in-process research and development expenses

Selling, general and administrative expenses

Change in fair value of contingent consideration

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Vertex Pharmaceuticals

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vertex Pharmaceuticals reports robust earnings, eyes growth in diverse therapies

Vertex Pharmaceuticals delivered strong financial results, provided optimistic revenue guidance for 2023, and emphasized investments in R&D and commercial capabilities. The company faces challenges with escalating costs and the need for clearer long-term financial goals. However, Vertex remains well-positioned to capitalize on growth opportunities in the healthcare market.

Vertex Pharmaceuticals reports robust Q1 growth and innovative pipeline

Vertex Pharmaceuticals had a strong Q1 2023 performance with revenue growth and ongoing investments in innovative therapies.
The company faces challenges in managing operating expenses and ensuring successful launches amidst competitive pressures.
However, Vertex's strengths lie in its diverse pipeline, regulatory approvals, and focus on transformative therapies.
Opportunities exist in addressing unmet medical needs, pursuing revenue growth in pain relief markets, and advancing non-opioid treatments.

Vertex Pharmaceuticals reports robust Q2 growth and pipeline advancements

Vertex Pharmaceuticals showed strong revenue growth and pipeline progress.
Challenges include slower uptake for gene therapies and market access.
Opportunities lie in reimbursement models, new therapy launches, and program advancements.
Overall, Vertex is strategically positioned for growth and innovation.

Vertex Pharmaceuticals reports strong Q3 growth and pipeline optimism

Vertex Pharmaceuticals shows solid financial performance and a robust pipeline of innovative therapies.
Challenges include navigating patient complexities, regulatory reviews, and market differentiation.
Opportunities lie in market expansion, therapeutic advancements, and strategic growth initiatives.
Overall, Vertex's focus on autonomy, innovation, and financial strength positions it for future success.

Vertex Pharmaceuticals reports robust Q4 earnings and strategic advancements

Vertex Pharmaceuticals delivered a strong performance in Q4 2023, driven by revenue growth, positive trial outcomes, and strategic advancements in its pipeline.
The company's focus on commercial diversification, regulatory approvals, and upcoming milestones in 2024 position Vertex well for continued success and growth.
While facing challenges related to patient targeting, physician capacity, and market differentiation, Vertex has opportunities to innovate, expand its reach, and enhance market positioning.
Overall, Vertex Pharmaceuticals' 2023 achievements, financial strength, and strategic initiatives underscore a promising outlook for the company's future growth and success.

Vertex Pharmaceuticals reports strong Q1 earnings and pipeline advancements

Vertex Pharmaceuticals demonstrated robust financial performance and strategic advancements in its pipeline and acquisitions, positioning itself for continued growth.
While facing challenges in commercialization and policy landscape, Vertex's strong financial position and innovative capabilities provide a solid foundation for future success.
With a focus on rare diseases, pain management, and revenue diversification, Vertex is poised to capitalize on market opportunities and drive innovation in healthcare.

Vertex Pharmaceuticals delivered strong revenue growth driven by key product demand, while facing increased operating expenses.
The company is focused on expanding its pipeline and accelerating new therapy launches amidst regulatory and commercial challenges.
Anticipation is high for upcoming launches like vanzacaftor and suzetrigine, signaling potential growth opportunities for Vertex.

Vertex Pharmaceuticals excels in Q3, poised for innovative growth

Vertex Pharmaceuticals demonstrated robust financial performance, highlighted by revenue growth and promising early launches. The company's strong R&D pipeline and strategic focus on commercialization underscore its commitment to driving innovation and growth. Addressing analyst inquiries and seizing growth opportunities will be key for Vertex's continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Vertex (VRTX) inks an all-cash deal to buy privately-held Semma Therapeutic. The acquisition will add pre-clinical type I diabetes candidates to its pipeline.

Vertex (VRTX) Inks All-Cash Deal to Acquire Semma for $950M

The biotech just announced a potentially game-changing acquisition.

Vertex Pharmaceuticals' $950 Million Bet on Curing Type 1 Diabetes Could Have an Astronomical Payoff

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) has seen a lot of choppy trading in 2019, rising from about $164 at the start of the year to near $195 during the first month of 2019 alone.

Vertex Scores Key Analyst Upgrade on Top of Making an Acquisition

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) will acquire Semma Therapeutics, a privately held biotechnology company that uses of stem cell-derived human islets as a potentially curative treatment for type 1 diabetes, for $950 million in cash.

Vertex To Acquire Diabetes Treatment Company Semma Therapeutics For $950M

ABIOMED

Shockwave Medical

These healthcare winners have such strong competitive advantages that their theme song could be MC Hammer's "U Can't Touch This."

3 Healthcare Stocks That Have a Killer Advantage

Amgen

REGENXBIO

Patent cliffs and pipeline risks are among the reasons these biologic drug specialists are attractively priced today.

Three Top Biotech Stocks, to Buy Right Now

VTNR is well positioned to benefit from increased demand and, likely, higher prices, for IMO 2020 compliant low sulphur fuel sales beginning January 1st, 2020.

Vertex Energy, Inc: With IMO-2020 Around The Corner It's Time To Revisit This Refiner

TechnipFMC

Constellation Brands

The stock charts of FTI, VRTX and STZ are knocking on the doors of major moves, even if the broad market isn't.
The post 3 Big Stock Charts for Tuesday: TechnipFMC PLC, Vertex Pharmaceuticals and Constellation Brands appeared first on InvestorPlace.

3 Big Stock Charts for Tuesday: TechnipFMC PLC, Vertex Pharmaceuticals and Constellation Brands

Allakos Inc

Biohaven Pharmaceutical Hld

Amicus Therapeutics

Jazz Pharmaceuticals

Golden crosses and death crosses are common signals in technical analysis and refer to the relationship between short-term and long-term moving averages.

Vertex Pharmaceuticals and Other Biotech Stocks With Recent Golden Crosses

EVP, Global Research and CSO of Vertex Pharmaceuticals Inc (30-Year Financial, Insider Trades) David Altshuler (insider trades) sold 12,501 shares of VRTX on 08/19/2019 at an average price of $186.38 a share.

Vertex Pharmaceuticals Inc (VRTX) EVP, Global Research and CSO David Altshuler Sold $2.3 million of Shares

After seventeen months in the works, Vertex Energy announced a partnership transaction with two phases. The transaction will both fund capital needs and help pay down long-term debt obligations.

Vertex Energy's Critical Pilot Project

Vertex (VRTX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Surging Earnings Estimates Signal Upside for Vertex (VRTX) Stock

Alexion Pharma

Two great biotechs focused on rare diseases. But one of them gets the nod as the better pick.

Better Buy: Vertex Pharmaceuticals (VRTX) vs. Alexion Pharmaceuticals (ALXN)

Amazon

Charter Communications

Salesforce

Intercontinental Exchange

Johnson Controls

Micron Technology

Netflix

NVIDIA

Investors know it's not easy to find companies already worth tens of billions that can still expand their revenues rapidly. But these giants show it's not impossible.

The 10 Largest-Cap Growth Stocks

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Vertex (VRTX).

Is Vertex (VRTX) a Great Growth Stock?

Vertex Energy, Inc. (VTNR) CEO Benjamin Cowart on Q2 2019 Results - Earnings Call Transcript

EVP\Chief Commercial Officer of Vertex Pharmaceuticals Inc (30-Year Financial, Insider Trades) Stuart A Arbuckle (insider trades) sold 3,708 shares of VRTX on 08/05/2019 at an average price of $177.22 a share.

Vertex Pharmaceuticals Inc (VRTX) EVPChief Commercial Officer Stuart A Arbuckle Sold $657,132.

A dominant cystic fibrosis franchise drives cash flow.

Vertex Has "Significant Financial Firepower"

Find out how concerned Vertex investors should be about a potential new cystic fibrosis treatment.

Will This Asteroid Heading Toward Vertex Pharmaceuticals Make Impact?

Vertex (VRTX) beats on earnings and sales in second-quarter 2019. The company lifts its full-year revenue guidance, led by a solid CF products' performance, especially Symdeko.

Vertex (VRTX) Beats on Q2 Earnings, Ups CF Product Sales View

Vertex Pharmaceuticals Incorporated (VRTX) CEO Jeff Leiden on Q2 2019 Results - Earnings Call Transcript

Vertex Pharmaceuticals earnings of $1.26 per share, minus some items, on $941.3 million in sales beat Wall Street estimates Wednesday. Vertex stock jumped on raised product sales guidance.

Vertex Tops Quarterly Estimates And Raises Guidance; Shares Pop

CRISPR Therapeutics

Editas Medicine

Intellia Therapeutics

Regeneron Pharmaceuticals

The CRISPR pioneer is taking a slow-and-steady approach to drug development. If peers are overlooking one key element of gene editing, that approach could pay off.

Is Intellia Therapeutics a Buy?

Incyte

Biotech stocks have been looking rough lately, and these four names have been helping to lead the charge lower.

4 Biotech Stocks Sliding Lower

On Vertex's (VRTX) second-quarter earnings call, investor focus will be on the adoption of its newest CF drug Symdeko and the update on its NDA filing for the VX-445 triple combination regimen.

News for Vertex Pharmaceuticals Stock (VRTX)